N-Methyl-1-(1H-pyrrol-2-yl)methanamine | 26052-05-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Methyl-1-(1H-pyrrol-2-yl)methanamine
• CAS: 26052-05-1
• 化学式: C₆H₁₀N₂
• mdl: MFCD09965839
• 分子量: 110.16
• InChiKey: NOARPNKCSMTOJD-UHFFFAOYSA-N

物化性质

• 沸点：
  84-85 °C(Press: 11 Torr)
• 密度：
  1.007±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  27.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-Methyl-1-(1H-pyrrol-2-yl)methanamine 、 sodium nitrite 、 溶剂黄146 生成 maleimidemonooxime
  参考文献：
  名称：

  LOEPPKY, R. N.;OUTRAM, J. R.;TOMASIK, W.;FAULCONER, J. M., TETRAHEDRON LETT., 1983, 24, N 40, 4271-4274

  摘要：

  DOI：

文献信息

• [EN] NON-ATP/CATALYTIC SITE p38 MITOGEN ACTIVATED PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINE KINASE ACTIVÉS PAR LE MITOGÈNE P38 DE SITE NON ATP/CATALYTIQUE
  申请人：UNIV MARYLAND

  公开号：WO2020118194A1

  公开（公告）日：2020-06-11

  Compounds that inhibit p38α MAPK protein, and methods of using the same, are provided for treating or preventing diseases such as cancer or inflammatory diseases.

  提供了抑制p38α MAPK蛋白的化合物，以及使用这些化合物治疗或预防癌症或炎症性疾病的方法。
• [EN] HEPATITIS B ANTIVIRAL AGENTS<br/>[FR] AGENTS ANTIVIRAUX DE L'HÉPATITE B
  申请人：ENANTA PHARM INC

  公开号：WO2020247575A1

  公开（公告）日：2020-12-10

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了化合物的结构式(I)，或其药学上可接受的盐：这些化合物抑制由乙型肝炎病毒（HBV）编码的蛋白质或干扰乙型肝炎病毒的生命周期功能，并且还可作为抗病毒药剂使用。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HBV感染的受试者。该发明还涉及通过给予含有本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• N-(HETEROCYCLE-METHYL)ALKYLAMINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND BACTERICIDE
  申请人：Kureha Chemical Industry Co., Ltd.

  公开号：EP1391450A1

  公开（公告）日：2004-02-25

  A N-heterocyclicmethyl-alkylamine derivative according to the present invention is a N-heterocyclicmethyl-alkylamine derivative represented by the following general formula (I): or an acid addition salt thereof. [in the formula, R1 represents a heterocycle which has at least one nitrogen atom as a hetero atom and may have a substituent on a ring; R2 represents a hydrogen or the like; R3 represents an alkyl group having a carbon number of 1 to 5 or the like; R4 represents an alkyl group having a carbon number of 1 to 5 or the like; when R4 is an alkyl group having a carbon number of 1 to 5 or a halogenated alkyl group having a carbon number of 1 to 5, carbon atoms in R3 and R4 may be bonded to form a ring structure; m represents an integer of 1 to 3; R5 represents a cycloalkyl group or the like described by the following formula (III): (in the formula, Y and Z each represents a hydrogen atom or the like, the letter p represents an integer of 2 to 5, and the groups described by CYZ may be each the same or different), when m is 1 and R4 is a hydrogen atom, R5 is a cycloalkyl group describedby the foregoing formula (III).]

  根据本发明，N-杂环甲基-烷基胺衍生物是由以下通式（I）代表的 N-杂环甲基-烷基胺衍生物： 或其酸加成盐。 [式中，R1 代表杂环，该杂环至少有一个氮原子作为杂原子，并可在环上有取代基；R2 代表氢或类似物；R3 代表碳原子数为 1 至 5 的烷基或类似物；R4 代表碳原子数为 1 至 5 的烷基或类似物；当 R4 是碳原子数为 1 至 5 的烷基或碳原子数为 1 至 5 的卤代烷基时，R3 和 R4 中的碳原子可以键合形成环状结构；m 代表 1 至 3 的整数；R5 代表下式（III）所述的环烷基或类似基团： (式中，Y 和 Z 分别代表氢原子或类似物，字母 p 代表 2 至 5 的整数，CYZ 所述基团可以相同或不同)，当 m 为 1 且 R4 为氢原子时，R5 为前式(III)所述的环烷基]。
• N-(heterocycle-methyl)alkylamine derivative, process for producing the same, and bactericide
  申请人：Ito Atsushi

  公开号：US20050101783A1

  公开（公告）日：2005-05-12

  A N-heterocyclicmethyl-alkylamine derivative according to the present invention is a N-heterocyclicmethyl-alkylamine derivative represented by the following general formula (I): or an acid addition salt thereof. [in the formula, R 1 represents a heterocycle which has at least one nitrogen atom as a hetero atom and may have a substituent on a ring; R 2 represents a hydrogen or the like; R 3 represents an alkyl group having a carbon number of 1 to 5 or the like; R 4 represents an alkyl group having a carbon number of 1 to 5 or the like; when R 4 is an alkyl group having a carbon number of 1 to 5 or a halogenated alkyl group having a carbon number of 1 to 5, carbon atoms in R 3 and R 4 may be bonded to form a ring structure; m represents an integer of 1 to 3; R 5 represents a cycloalkyl group or the like described by the following formula (III): (in the formula, Y and Z each represents a hydrogen atom or the like, the letter p represents an integer of 2 to 5, and the groups described by CYZ may be each the same or different), when m is 1 and R 4 is a hydrogen atom, R 5 is a cycloalkyl group described by the foregoing formula (III).]

  根据本发明，N-杂环甲基-烷基胺衍生物是由以下通式（I）代表的 N-杂环甲基-烷基胺衍生物： 或其酸加成盐。 [式中，R 1 代表至少有一个氮原子作为杂原子的杂环，并可在环上有取代基；R 2 代表氢或类似物；R 3 代表碳原子数为 1 至 5 的烷基或类似物； R 4 代表碳原子数为 1 至 5 的烷基或类似物；当 R 4 是碳原子数为 1 至 5 的烷基或碳原子数为 1 至 5 的卤代烷基时，R 3 和 R 4 中的碳原子可以键合形成环状结构；m 代表 1 至 3 的整数；R 5 代表下式（III）所述的环烷基或类似基团： (式中，Y 和 Z 分别代表氢原子或类似物，字母 p 代表 2 至 5 的整数，CYZ 所述基团可以相同或不同），当 m 为 1 且 R 4 是氢原子时，R 5 是前述式 (III) 所述的环烷基]。
• Imidazole compound for use as an intermediate in the production of cinnamide compounds
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2261218B1

  公开（公告）日：2013-04-03